`l09—MS-301 and l09—MS-302
`
`Thursday, 8"‘ February 2007
`
`DISTRIBITION I ATTENDEES
`
`BIIB Attendees
`
`atna , noamaneni
`
`Pliill Gallacher
`
`Kate Dawson
`
`
`
`
`Names in BOLD attended this ulccmiz
`
`Clinical Ifggdatez
`109318301 Shidv Status Ugdate
`o
`120 sites Sponsor approved
`0
`150 PSSV coiuplclcd — cum-iitly following up Wllll US. Roiuzmia & Bulgana to gm: 160 sites
`Australia:
`-
`SIV dalc 20"‘ ;\rlarcl1
`o
`update: 6 patient: identified:
`I
`1 Rcjected
`dosing schedule
`'
`3 currently IL'\"lC\Vll1g l(‘l-‘
`SH: to follow up
`I
`2 clltrcmly reviewing medical history
`
`BG12 SMT Meeting Minutes
`
`Page 1 0‘ 6
`
`Biogen Exhibit 2198
`Coalition v. Biogen
`IPR2015-01993
`
`
`
`Belgium:
` SIV dates for Belgium have been targeted for between 15th – 28th Feb
`Post meeting note - Confirmed SIV dates
` 19th Feb,
` 23rd March
` Awaiting Regulatory approval – 15th March final date (60 days) for approval, however should receive
`approval before this date
`Post meeting note - Belgium approval received 13th Feb 07 – awaiting confirmation letter
`
` 20th Feb,
`
` 13th March &
`
`
`Canada:
` SIV date 28th Feb
`
` Local EC submissions have been completed, however those sites will not be initiated until March 07
`
` update: 1 outstanding document (contract). Once received site can be activated and drug
`released.
` and local affiliate have all been in contact with site. If nothing has been received from
`site by Friday 9th Feb – K. Dawson to call and follow up with site
`
`New Zealand:
`
`
`
` SIV dates 1st – 15th March
`
`109MS302 Study Status Update
` 100 PSSV completed
` 8 PSSV scheduled
`
`
`
`Canada:
`
`:
`o Local EC submitted on 7th Feb
`o Potential FPI site
`o SIV scheduled for last week March 07
`:
`o Prefers 301 study
`o Has confirmed to submit to MRI committee on 20th Feb – need clarification what this means.
` to follow up
`:
`o Need site to confirm if they can meet the submission date of 20th Feb
`:
`o Site will not commit to making a submission.
`
`
`
`
`
`BG12 SMT Meeting Minutes
`
`Page 2 of 6
`
`
`
`Russia:
` Potentially 3 sites could be initiated in April
`
`Other:
` Target countries: Canada, Russia, NZ, Germany and Czech
` Timelines:
`o FPI – May 07
`o LPI – Q2/2008: Jun 08
`
`INEC Members Update
` 3 members
` have been a few issues with contracts
`currently approaching other potential members
`
`
`Data Management Update
` 301 & 302 CRFs including the questionnaires will be in the warehouse by 14th Feb
` CRFs can be ordered by
`
`
` for the addresses
` to contact
` Regulatory to share info with DM regarding which CRF version is being submitted for each country
`
`:
`o Version 2 of CRF has not been submitted. Awaiting comments as these have to be included into
`the submission
`o
`Important to submit Version 2 before Version 3 is released
`Clinical Operations Update
` Copaxone label requirements: label is required stating “for clinical trial use”
` Clinical operations to set up a meeting with regulatory to discuss and clarify regulatory requirements for
`the new backup countries
` Clinical operations need details of backup countries in order to ensure sufficient supplies are available
` Clinical operations to clarify if current label is acceptable in India – may need to be revised
`
`Protocol Amendment update
`
` Sign off of amendments – 22nd Feb
` Version 1 of draft has been reviewed. Version 2 to be reviewed 9th Feb
`
`
`
`
`
` Regulatory update:
`o
`IMPD has now been finalized
`IB addendum should be released today - 8th Feb
`
`
`BG12 SMT Meeting Minutes
`
`Page 3 of 6
`
`
`
`BG12 SMT Meeting Minutes
`
`Page 4 of 6
`
`
`
`Page 5 of 6
`
`
`
`BG12 SMT Meeting Minutes
`
`
`
`8th February 2007
`
`Page 6 of 6